Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.
Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.
Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.